Project Grant R01AR085068
Award Date 9/15/25
Completion Date 8/31/30
Dollars Obligated $599K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- This $1,104,029 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in non-ambulatory individuals with Duchenne muscular dystrophy (DMD). The research will be conducted over a 3-year period from November 1, 2024 to October 31, 2027. The funding will enable the University of...
- The University of Florida Division of Sponsored Research received a $536,800 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund a 3-year exploratory clinical trial to investigate the potential of the drug tadalafil, combined with structured exercise training, to improve muscle pathophysiology and function in individuals with Duchenne...
- This $953,125 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in nonambulatory individuals with Duchenne muscular dystrophy. The research project will run from November 1, 2024 to October 31, 2027 and aims to advance understanding of neurodegenerative diseases...
- This federal Project Grant award of $671,240 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to develop enhanced dystrophin gene therapies for Duchenne muscular dystrophy (DMD). The University of Washington will conduct this research from January 2025 through December 2029. The project aims to design and test micro-, mini-, and full-length dystrophin gene...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,829,773 project grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Florida. The grant, awarded on September 5, 2025, will fund research to investigate the mechanisms by which sepsis harms muscles and impedes proper regeneration, with the goal of developing new strategies to improve septic patients' recovery of skeletal muscle function...
- The University of Florida was awarded a $1,166,594 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, with a performance period from September 1, 2025 to August 31, 2029, will fund research to investigate "Early Cardiac Biomarkers of Inflammation and Remodeling in DMD" at the University's location in Gainesville, FL. This research aims to transform healthcare for military service members, veterans, and the...
- The University of Florida (UF) received a $1,524,836 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding and targeting common mechanisms of myotonic dystrophy types 1 and 2 using novel repeat expansion mouse models. The grant, which began on September 1, 2023 and will continue through August 31, 2027, supports UF's cutting-edge biomedical research efforts to transform healthcare for Service...
- This $1,525,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports foundational studies at the University of Florida to understand the phenotypic, region-specific, and cell-specific dysregulation in the central nervous system of individuals with myotonic dystrophy. The 4-year award, effective May 15, 2024, will enable the university to conduct innovative research to advance the understanding of this neurological...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $295,294 Phase I SBIR project grant (CFDA 93.846) to Gigamune, Inc. to develop a novel lentiviral gene delivery platform for in vivo delivery of the full-length dystrophin gene to muscle cells. The goal is to create an efficient and targeted approach for gene therapy to treat Duchenne muscular dystrophy, a severe genetic disorder causing muscle wasting. The project aims to leverage Gigamune's...
- The University of Florida was awarded a $5.796 million Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) for the period of September 1, 2023 through August 31, 2027. The grant will support the development of clinical candidates for the treatment of Myotonic Dystrophy at the University's location in Gainesville, Florida. As the prime awardee, the University will leverage its expertise in biomedical research to...